Abeona reports Q1 2026 with rising ZEVASKYN treatments and new T-cell therapy licensing.

Abeona Therapeutics reported Q1 2026 financial results showing increased adoption of its cell therapy ZEVASKYN, treating three patients in the quarter and expanding its Qualified Treatment Center network to six sites. The company licensed a novel engineered T-cell therapy, ABO-701, targeting advanced prostate cancer, aiming for IND filing and human trials in late 2027. Financially, Abeona posted $8.7 million in net product revenue, up from $2.4 million last quarter, with a net loss of $17.1 million due to increased commercial and R&D investments. The company plans to focus on commercializing ZEVASKYN while advancing ABO-701 development.